1 Sakata Y, "The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia" 77 : 1949-1957, 1991
2 Zhu HH, "The simpler, the better : oral arsenic for acute promyelocytic leukemia" 134 : 597-605, 2019
3 Stein E, "The coagulopathy of acute promyelocytic leukaemia revisited" 22 : 153-163, 2009
4 Norsworthy KJ, "Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide : a SEER-Medicare analysis" 34 : 3082-3084, 2020
5 Sanz MA, "Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy : a multicenter study by the PETHEMA group" 103 : 1237-1243, 2004
6 Sanz MA, "Management of acute promyelocytic leukemia : updated recommendations from an expert panel of the European LeukemiaNet" 133 : 1630-1643, 2019
7 Sanz MA, "Management of acute promyelocytic leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet" 113 : 1875-1891, 2009
8 Martinez-Cuadron D, "Longterm outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy" 32 : 21-29, 2018
9 Cicconi L, "Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia : update of the APL0406 Italian-German randomized trial" 34 : 914-918, 2020
10 Gill H, "Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens : a 15-year prospective study" 124 : 2316-2326, 2018
1 Sakata Y, "The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia" 77 : 1949-1957, 1991
2 Zhu HH, "The simpler, the better : oral arsenic for acute promyelocytic leukemia" 134 : 597-605, 2019
3 Stein E, "The coagulopathy of acute promyelocytic leukaemia revisited" 22 : 153-163, 2009
4 Norsworthy KJ, "Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide : a SEER-Medicare analysis" 34 : 3082-3084, 2020
5 Sanz MA, "Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy : a multicenter study by the PETHEMA group" 103 : 1237-1243, 2004
6 Sanz MA, "Management of acute promyelocytic leukemia : updated recommendations from an expert panel of the European LeukemiaNet" 133 : 1630-1643, 2019
7 Sanz MA, "Management of acute promyelocytic leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet" 113 : 1875-1891, 2009
8 Martinez-Cuadron D, "Longterm outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy" 32 : 21-29, 2018
9 Cicconi L, "Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia : update of the APL0406 Italian-German randomized trial" 34 : 914-918, 2020
10 Gill H, "Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens : a 15-year prospective study" 124 : 2316-2326, 2018
11 Avvisati G, "Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia : final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up" 100 : 3141-3146, 2002
12 Eghtedar A, "Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide" 56 : 1342-1345, 2015
13 Platzbecker U, "Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia : final results of the randomized Italian-German APL0406 Trial" 35 : 605-612, 2017
14 Cicconi L, "Current management of newly diagnosed acute promyelocytic leukemia" 27 : 1474-1481, 2016
15 Tallmann MS, "Curative therapeutic approaches to APL" 83 (83): S81-S82, 2004
16 Dombret H, "Combined therapy with all-trans-retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage" 6 : 1237-1242, 1992
17 Li X, "Combined chemotherapy for acute promyelocytic leukemia : a meta-analysis" 22 : 450-459, 2017
18 Krsnik I, "Bleeding in acute promyelocytic leukemia(APL) : fibrinolysis or defibrination?" 33 : 39-41, 1991
19 Hoyle CF, "Beneficial effect of heparin in the management of patients with APL" 68 : 283-289, 1988
20 Ades L, "Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia : analysis of a randomized trial(APL 2006)by the French Belgian Swiss APL group" 103 : 2033-2039, 2018
21 Cordonnier C, "Acute promyelocytic leukemia in 57 previously untreated patients" 55 : 18-25, 1985
22 Coombs CC, "Acute promyelocytic leukemia : where did we start, where are we now, and the future" 5 : e304-, 2015
23 Marty M, "Acute promyelocytic leukemia : retrospective study of 119 patients treated with daunorubicin" 26 : 371-378, 1984
24 Wang ZY, "Acute promyelocytic leukemia : from highly fatal to highly curable" 111 : 2505-2515, 2008
25 Kingsley EC, "Acute promyelocytic leukemia" 146 : 322-327, 1987